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IFN--producing CD4 T cells, although important for protection
against acute Toxoplasma gondii infection, can cause gut pathol-
ogy, which may prove to be detrimental for host survival. Here we
show that mice lacking IL-15 gene develop a down-regulated
IFN--producing CD4 T cell response against the parasite, which
leads to a reduction in gut necrosis and increased level of survival
against infection. Moreover, transfer of immune CD4 T cells from
WT to IL-15/ mice reversed inhibition of gut pathology and
caused mortality equivalent to levels of parental WT mice. Down-
regulated CD4 T cell response in the absence of IL-15, manifested
as reduced antigen-specific proliferation, was due to defective
priming of the T cell subset by dendritic cells (DCs) of these animals.
When stimulated with antigen-pulsed DCs from WT mice, CD4 T
cells from IL-15/ mice were primed optimally, and robust prolif-
eration of these cells was observed. A defect in the DCs of knockout
mice was further confirmed by their reduced ability to produce
IL-12 upon stimulation with Toxoplasma lysate antigen. Addition
of exogenous IL-15 to DC cultures from knockout mice led to
increased IL-12 production by these cells and restored their ability
to prime an optimal parasite-specific CD4 T cell response. To our
knowledge, this is the first demonstration of the role of IL-15 in the
development of CD4 T cell immunity against an intracellular
pathogen. Furthermore, based on these observations, targeting of
IL-15 should have a beneficial effect on individuals suffering from
CD4 T cell-mediated autoimmune diseases.
CD4 T cells  dendritic cells
Cytokines play an important role in protection against an obli-gate intracellular parasite Toxoplasma gondii (1). Among the
cytokines, IFN- is central for protection against both acute (2) and
chronic infection (3). Mice lacking IFN- gene are highly suscep-
tible to T. gondii infection (4, 5), and treatment with anti-IFN-
antibody can cause reactivation of latent disease (3). In addition to
IFN-, other cytokines such as IL-12 (6, 7), IL-7 (8), and IL-15 (9,
10), by their ability to stimulate IFN--producing natural killer
(NK), CD4, and CD8 T cells, also have been reported to be
involved in host resistance. IFN- is primarily secreted during acute
infection by NK and CD4 T cells (11, 12), whereas over the long
term, IFN--producing CD8 T cells serve as major effector cells
responsible for keeping chronic infection in a dormant state (3, 13).
IL-12 is produced very early during T. gondii infection (14) and
has been reported to play an important role in the induction of
CD4 T cell effectors (15, 16), which are an important source of
IFN- production during the acute phase of infection (7). Mutant
animals lacking IL-12 (17) or normal mice treated with anti IL-12
antibody (6) exhibit severe reduction in IFN- response against the
parasite and are highly susceptible to infection. Similarly, studies
from our laboratory have shown that exogenous IL-7 administra-
tion can enhance the IFN--producing cytotoxic T lymphocyte
levels in infected animals (8). The importance of another -chain
cytokine, IL-15, in protective immune response againstT. gondii has
been demonstrated (18). IL-15 is a pleiotropic cytokine produced
by both hematopoietic and nonhematopoietic cells (19). It has been
reported to be important for the persistence of CD8 T cell
memory response against infectious diseases (20, 21) and tumor
models (22). The cytokine is also considered to be a key regulator
ofNK cell development, homeostasis, and activity (23, 24). The role
of IL-15 in the induction of long-term memory CD8 T cell
response againstT. gondii has been demonstrated (18).However, its
contribution in the induction of primary immune response during
acute T. gondii infection has not been extensively studied. In a
recent report with IL-15-deficient mice, Lieberman et al. (25)
demonstrated that the lack of IL-15 gene does not affect the
outcome of infection in mice challenged i.p. with T. gondii. In the
present study, we used IL-15/mice to evaluate the importance of
this cytokine in the survival and tissue inflammation of animals
during per-oral (p.o.) challenge.
Results
IL-15/ Mice Have Reduced Susceptibility to T. gondii Infection. To
determine the importance of IL-15 during acute T. gondii infection,
knockout and WT mice were challenged orally with 25 cysts of T.
gondii. Although 70% of the WT mice succumbed to infection by
day 12 postinfection (p.i.) (Fig. 1), mortality in the knockout mice
was not observed until day 19 p.i., and only two of eight mice had
died when the experiment was terminated. Conversely, when the
mice were infected i.p., no difference between WT and knockout
micewas observed. Three of sixmice fromeach groupdied between
days 40 and 45 p.i., whereas the remaining animals from both
groups survived until the termination of the experiment (data not
shown).
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Fig. 1. Survival of IL-15/ mice against T. gondii infection. IL-15/ (n  8)
and WT (n9) mice were infected orally with 25 cysts ofT. gondii. Survival was
monitored on a daily basis. The study was performed twice. Data are repre-
sented as cumulative percentage of both experiments.
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Histopathological analysis of p.o. infectedmice was performed at
day 10 p.i. Sections of small bowel and liver from infected parental
mice showed the patchy epithelial necrosis and scattered hepatic
inflammatory nodules (Fig. 2 A and B) typical of the hyperimmune
response to T. gondii infection (11, 26). IL-15/ mice showed
similar changes, with perhapsmore inflammation than the controls,
but the affected segments of bowel were minimal and most gut
epithelia were intact (Fig. 2C). As expected, liver from WT mice
showed extensive fatty changes in hepatocytes (Fig. 2B), whereas
changes in IL-15/ mice were less severe (Fig. 2D).
Analysis of Parasite Load. Differences in the parasite burden be-
tween the tissues (gut, liver, spleen, and brain) ofWT and IL-15/
mice were analyzed by quantitative PCR at day 10 p.i. Compared
with parental WT animals, knockout mice had 3- to 4-fold higher
parasite load in the gut and spleen (P  0.01) (Fig. 3). These
observations demonstrate that although knockout mice have ele-
vated parasite load, they survive longer because of reduced inflam-
matory response to infection.
IFN- Response.BecauseT. gondii-mediated inflammatory response
primarily depends on IFN--producing CD4 T cells (11), we
evaluated the T cell subset induced in response to infection.
IL-15/ andWT controls were killed at day 10 p.i. Purified CD4
and CD8 T cell populations from spleen and mesenteric lymph
node (MLN) were analyzed for IFN- production by intracellular
staining. The percentage of IFN--producing CD4 T cells in both
MLN and spleen were significantly reduced (P  0.005 and P 
0.01) in the knockout mice (Fig. 4 A and B). Similarly, a reduced
percentage of IFN--positive CD8 T cells was observed in the
mutant animals. To confirm that reduced gut inflammatory re-
sponse in the IL-15/ mice was due to decreased IFN- produc-
tion, the cytokine message in the gut was analyzed by real-time
Fig. 2. Photomicrographs of representative organs from T. gondii-infected
IL-15/and WT mice. Mice were killed at day 10 p.i., and organs (liver and gut)
were collected. Liver and gut sections were stained with hematoxylineosin.
(A) WT gut. An example from a patchy segment of the small bowel mucosa
shows superficial loss of epithelium and congestion of vessels. (Scale bar: 100
m.) (B) WT liver. One of numerous parenchymal nodules of inflammatory
cells including mononuclear and polymorphonuclear cells. Some necrotic cells
are seen with significant fatty change in surrounding hepatocytes. (Scale bar:
50 m.) (C) Knockout gut. Full thickness inflammation penetrates a small,
scattered segment of the small bowel, with comparatively less necrosis and
acute inflammation throughout the tissue. Dark vertical lines are artifactual
folds of the tissue. (Scale bar: 100 m.) (D) Knockout liver. Scattered paren-
chymal nodules are composed predominantly of mononuclear cells with some
polymorphonuclear cells, with evidence of scattered hepatocyte necrosis and
minimal fatty change. (Scale bar: 50 m.)
Fig. 3. Number of parasites per 0.4g of tissue DNA in the tissues of IL-15/
and parental WT mice. IL-15/and WT mice (n4) were infected with 25 cysts
of T. gondii. At day 10 p.i., tissue DNA was isolated from brain, liver, gut, and
spleen. The level of parasite load in the tissues was determined by quantitative
PCR. Data are presented as mean SD and are representative of two separate
experiments.
Fig. 4. Analysis of IFN--producing T cells from IL-15/ mice infected with
T. gondii. Mice were infected p.o. with T. gondii cysts as mentioned above.
MLN (A) and splenocytes (B) were harvested at day 10 p.i., pooled (n 3), and
stimulated in vitro for 4 h. Cells were labeled for CD4 or CD8 before
intracellular staining for IFN-. Data are presented as percentage (mean SD)
of CD4 or CD8 T cells positive for IFN- and are pooled from two different
experiments. (C) Total gut RNA was isolated from WT and IL-15/ mice (n 
4) at day 7 p.i. and analyzed for IFN-mRNA expression, normalized to -actin
mRNA levels. Relative expression was measured by using the mean from each
group and the formula RTL (relative transcript level) 2Ct 1000. Statistical
bars represent the mean  SD.
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PCR. As shown in Fig. 4C, in comparison with WT animals, guts
of knockout mice exhibited significantly lower IFN- message in
response to infection (P  0.001).
To further establish that knockoutmice were unable to induce an
optimal CD4 T cell response, lympho-proliferation assays were
performed. At day 10 p.i., purified CD4 T cells from MLN were
stimulated with Toxoplasma lysate antigen (TLA) and proliferation
measured. As compared with those ofWTmice, CD4T cells from
knockout animals exhibited significantly less proliferative response
to TLA stimulation (P  0.007) (Fig. 5). No differences in the
proliferation between the knockout and WT CD4 T cells in
response to Con A stimulation was observed (Fig. 5). Reduced
proliferation of CD4 T cells from knockout mice could be due to
diminished activation of these cells. CD4 T cells from MLN
of both WT and knockout mice were evaluated for activation
markers (CD44hi and CD62lo) (27), at day 10 p.i. by FACS analysis.
T. gondii infection led to a 3-fold increase in activated CD4 T
cells in the WT mice. Conversely no significant increase in
CD4CD44hiCD62lo population in response to Toxoplasma infec-
tion was observed in IL-15/ mice (data not shown).
Adoptive Transfer of CD4 T Cells. To establish that down-regulated
inflammatory response and increased survival of IL-15/micewas
due to poor CD4 T cell response, adoptive transfer studies were
performed. Purified CD4 T cells (1 107) from infected or naı¨ve
WTmice were transferred to knockout animals. Twenty-four hours
later the recipients were challenged with 25 cysts of T. gondii.
Histopathological analysis on the tissues (liver and gut) of recipient
animals was performed at day 10 p.i. Tissues from IL-15 knockout
mice infused with CD4 T cells from naı¨ve WT mice (Fig. 6 Aiia
and Aiib) resemble the infected controls treated with saline (Fig. 6
Aia and Aib), and both of these animals had mild pathology due to
infection. However, when infused with CD4 T cells from infected
WT mice, the knockout animals had much more extensive super-
ficial necrosis of gut epithelia (Fig. 6Aiiia) similar to that observed
in the WT controls (Fig. 2A). As expected, WT mice treated with
naı¨ve or immuneCD4T cells developed gut pathology in response
to T. gondii infection, similar to the levels of control WT mice
injected with saline (data not shown).
To determine the effect of adoptive transfer on the outcome of
infection, recipient animals were monitored for survival. As ex-
pected, control WT mice treated with saline exhibited early mor-
tality (days 8–10 p.i), and all of the animals were dead by day 10 p.i.
Fig. 6. Adoptive transfer of CD4 T cells from WT C57BL6 to IL-15/ mice.
Infected and uninfected mice (10 mice per group) were killed at day 10 p.i.,
and MLNs were harvested and pooled. CD4 T cells from the MLN were
isolated by affinity purification. Purified CD4 T cells (1  107) isolated from
naı¨ve or infected mice were transferred i.v. to IL-15/ mice (six mice per
group). The control mice (nontransferred knockout and WT) were injected
with an equal volume of saline. WT mice injected with immune CD4 T cells
were also included as controls. Twenty-four hours posttransfer the recipients
were challenged with 25 cysts of T. gondii. At day 10 postchallenge, two of six
mice were killed, and histopathological analysis on the tissues (gut and liver)
was performed (A). (Aia and Aib) Knockout mice plus saline. (Aia) Gut: An
example of one of a few areas of superficial loss of epithelium, also showing
a mild increase of inflammatory cells in the lamina propria. (Scale bar: 50m.)
(Aib) Liver: Scattered parenchymal nodules of mononuclear and polymorpho-
nuclear inflammatory cells are set among hepatic cells with mild fatty change.
(Aiia and Aiib) Knockout mice plus naı¨ve CD4 T cells. (Aaii) Gut: An area of
superficial necrosis of epithelium with minimal inflammation. (Scale bar: 100
m.) (Abii) Liver: An example of one of many nodules made up of mixed
inflammatory cells scattered throughout the parenchyma of the liver. (Scale
bar: 50 m.) (Aaiii and Abiii) Knockout mice plus immune CD4 T cells. (Aaiii)
Gut: An example of a segment of small bowel with extensive superficial
necrosis with moderate inflammation in the lamina propria. (Scale bar: 100
m.) (Abiii) Liver: One of many scattered nodules of mixed inflammatory cells
with hepatocyte necrosis and minimal fatty change. (B) The remaining four of
six mice were monitored for survival on daily basis. Data are pooled from two
experiments. (C) Purified CD4 T cells isolated from infected or uninfected
IFN-/mice were injected to naı¨ve IL-15/mice (1 107 cells per recipient).
Animals (six mice per group) were challenged orally with 25 cysts and moni-
tored for survival. Experiments were performed twice with similar results, and
the data are representative of one experiment.
Fig. 5. Antigen-specific proliferation and activation of CD4 T cells of
IL-15/ mice. Mice (n  3 per group) were infected orally with 25 cysts, and
animals were killed at day 10 p.i. MLNs from each group were harvested and
pooled, and CD4 T cells were isolated by affinity purification. Purified CD4
T cells (1 105 cells per well) were cultured with 1 105 irradiated feeder cells
and stimulated either with 15 gml TLA or 2 gml Con A. After 72-h
incubation, lympho-proliferation was assayed by [3H]thymidine incorpora-
tion. The experiment was performed twice with similar results, and the data
are representative of one experiment.
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(Fig. 6B). Similarly, as observed earlier, nominal death in the
saline-treated knockoutmicewas observedmuch later than theWT
mice, starting at day 20 p.i. Interestingly, transfer of immune CD4
T cells fromWT mice to IL-15/ recipients led to their mortality,
and80%recipients died at the same time asWT infected controls.
Conversely, transfer of naı¨ve CD4 T cells from WT to IL-15/
mice did not increase their mortality to T. gondii infection (Fig. 6B).
This group did not even exhibit nominal death observed in saline-
treated knockout animals. To determine that inflammatory re-
sponse in the knockout recipients depended on IFN- production
of donor CD4 T cells, adoptive transfer with CD4 T cells from
IFN-/ mice was performed. Unlike the recipients treated with
immune CD4 T cells from WT mice, the majority of knockout
mice treated with CD4 T cells from IFN- / animals survived
the infection, and only two of six mice died until the termination of
experiment (Fig. 6C).
Primary CD4 T Cell Response. Next, we determined whether down-
regulated CD4 T cell immunity in IL-15/ mice was due to
inadequate priming of this T cell subset. Because dendritic cells
(DCs) are known to play a key role in the initiation of immune
response (28, 29), we evaluated CD4 T cells priming against TLA
by DCs from IL-15/ and parental WT mice. DCs from MLN of
naı¨ve WT or knockout animals were isolated and pulsed with TLA
in an overnight culture. On the following day, purified CD4T cells
were added, and the proliferative response was subsequently mea-
sured. As expected, DCs from the WT mice induced an optimal
proliferation of CD4 T cells from the same strain of mice (Fig. 7).
Conversely, CD4 T cells from IL-15/mice showed significantly
lower (3-fold less) proliferation (P  0.001) when primed with
DCs from the same mice. However, when stimulated with antigen-
primed DCs of WT mice, CD4 T cells from knockout animals
exhibited an optimal proliferative response, which was almost
equivalent to the CD4 T cells from parental WT mice (Fig. 7).
CD4 T cells from both WT and IL-15/ mice showed signifi-
cantly lower proliferation (P  0.001 and P  0.03, respectively)
when primed with DCs from knockout animals. However, addition
of IL-15 to the cultures restored the ability of IL-15/ DCs to
prime CD4 T cells from both knockout and WT mice (P 0.001
and P  0.019, respectively) (Fig. 7).
IL-12 Production by DCs. The above observations suggest that down-
regulated CD4 T cell response in IL-15/ mice appears to be a
result of inefficient priming of these cells by DCs. In normal
immunocompetent mice, T. gondii infection induces a rapid and
large IL-12 production by DCs (14). Moreover, recent studies have
demonstrated that IL-15 treatment of DCs results in higher IL-12
production by these cells (28). To establish thatDCs fromknockout
mice are hypo-responsive to T. gondii infection, the level of IL-12
production by DCs from IL-15 knockout mice was evaluated.
Purified cells from knockout and WT mice were pulsed with TLA,
and IL-12 production in the supernatants was measured by ELISA.
As shown in Fig. 8, compared with parental WT mice, DCs from
knockout mice released significantly lower (almost 3-fold less)
IL-12 upon TLA stimulation (P 0.004). However, the addition of
exogenous IL-15 to cultures led to increase in IL-12 production by
knockoutDCs (P 0.002), and cytokine levels released in response
TLA stimulation were comparable with cells from WT animals
(Fig. 8).
Discussion
In the present studies, we demonstrate that mice lacking the IL-15
gene exhibited milder inflammatory reaction in response to oral T.
gondii infection. Despite the fact that the parasite levels in the
tissues of knockout mice, especially gut, were higher than the WT
controls, these animals survived T. gondii infection better than did
the parentalWTmice. Increased survival of IL-15/mice infected
p.o. with T. gondii is due to comparatively less gut necrosis in these
animals. Analysis of MLN and spleen showed that, as compared
with the WT animals, fewer IFN--producing CD4 T cells in
response to T. gondii infection in knockout mice are induced.
Suboptimal CD4 T cell immunity against the parasite in the
knockoutmicewas furthermanifested by decreased proliferation of
these cells in response to antigenic stimulation. Moreover, adoptive
transfer of normal immune CD4 T cells caused increased inflam-
matory response in the recipients, which led to their death. The
lower CD4 T cell response in the absence of IL-15 was due to
defective functioning of DCs as demonstrated by lowered IL-12
secretion by these cells in response to Toxoplasma antigens. Fur-
thermore, addition of IL-15 to DC cultures from knockout mice
restored their ability to secrete IL-12 and prime CD4 T cell
response. To our knowledge, this report is the first to demonstrate
the role of IL-15 in the induction of primary CD4 T cell response,
and it also emphasizes the importance of this cytokine against acute
T. gondii infection.
A recent report by Lieberman et al. (25) has shown that IL-15/
mice do not exhibit increased susceptibility to i.p. infection. In
agreement with these observations, we demonstrate that unlike p.o.
challenge, IL-15/ andWT animals exhibit similar mortality when
infection is carried via the i.p. route (data not shown). These
findings are very important because difference in the outcome of
parasite challenge based on the route of infection has not been
clearly demonstrated. The differences can be attributed to the
involvement of mucosal immune system during oral infection,
Fig. 7. Antigen-specific CD4 T cell priming of IL-15-deficient mice. DCs and
CD4 T cells from MLN of IL-15/ and WT mice (six to eight animals per group)
were isolated. After overnight incubation of DCs with 20 gml TLA, CD4 T
cells were added. Seventy-two hours later, proliferation was determined by
[3H]thymidine incorporation assay. The experiment was performed twice with
similar results, and the data are representative of one experiment.
Fig. 8. IL-15/ DCs produce less IL-12 in vitro. DCs were isolated from MLNs
of IL-15/ and WT mice (six to eight mice per group) and incubated overnight
(5  104 cells per well) with 20 gml TLA. After 24-h incubation, IL-12 levels
in supernatants were determined by ELISA. The experiment was performed
twice with similar results, and the data are representative of one experiment.
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which is known to play an important role in protection againstmany
pathogens (30), including T. gondii (31). Our findings suggest that
mucosal immune system, in addition to providing protective im-
munity against oral infection, may play an important role in
tailoring the peripheral immune response against T. gondii and
other orally acquired pathogens. This unstudied role of mucosal
immunity needs to be evaluated.
IL-15 has been described as a proinflammatory cytokine that
shares biologic activities with IL-2 (19) and is important for
generation of NK cell response (32). The role of IL-15 in the
homeostasis of CD8 T cell memory is well established (33–35).
Studies from our laboratory have shown that administration of
exogenous IL-15 prolongs CD8 T cell response against T. gondii
(9) and that blockade of this response inhibits the development of
long-term CD8 T cell immunity against the parasite (18). Simi-
larly, the role of IL-15 in the maintenance of memory CD8 T cell
immunity against other infectious disease has been described (20,
21, 36). Because of its proinflammatory properties, the role of IL-15
in a number of autoimmune diseases has been demonstrated
(37–39). It inhibits self-tolerance mediated by AICD and facilitates
the survival of self-directed memory CD8 T cells (40). McInnes
and colleagues (41) have reported abnormalities of IL-15 in rheu-
matoid arthritis patients and have suggested that IL-15 precedes
TNF- in the cytokine cascade. IL-15 has also been suggested to
have a pathogenic role in other inflammatory diseases, such as
sarcoidiosis (42), chronic hepatitis C (43), andulcerative colitis (44).
Antibodies against IL-15 have been used effectively in murine
models of autoimmune diseases, including Psoriasis (45). IL-15 has
also been shown to be overexpressed in the inflamed mucosa in
inflammatory bowel disease patients and responsible for enhance-
ment of local T cell activation, proliferation, and proinflammatory
cytokine production (37). It has been suggested that treatment with
anti IL-15 agents can serve as potential therapeutic regimen in these
patients (46).
As stated earlier, the importance of CD4T cell response against
T. gondii infection is well documented (2, 3, 47). During the acute
phase of the disease, CD4 T cells are the primary source of host
IFN- production (48), leading to immunopathology and ultimate
death of the animal (11, 26). CD4 T cells are known to play a
primary role in number of autoimmune diseases such as inflam-
matory bowel disease, Crohn’s disease, and experimental autoim-
mune encephalomyelitis (49–51). However, the importance of
IL-15 in the elicitation of primary CD4 T cell response and
subsequent effect on the pathogenesis of these diseases has not been
reported.
We demonstrate that in the absence of IL-15, down-regulated
CD4T cell immune response againstT. gondii infection is induced.
This reduction is due to impairment of DC response in these
animals as a result of which CD4 T cells are not primed to optimal
levels. These findings are supported by earlier reports, which
showed that IL-15–IL-15 receptor interaction is critical for early
activation of antigen-presenting cells (52). DCs are the primary
source of IL-12, which is released during very early stages of
infection (14). Our studies demonstrate thatDCs frommice lacking
IL-15 exhibit decreased IL-12 response to Toxoplasma stimulation
and are less effective in priming of CD4T cells, which in turn leads
to lower inflammatory response in the infected animal. These
findings are supported by recent observations demonstrating that
priming with IL-15-treated DCs can strongly polarize CD4 T cells
toward production of IFN- (28). Although the knockout animals
have a higher parasite load in comparison withWTmice, especially
in the gut, they survive the infection because of milder pathology in
the tissue. All of this is due to suboptimal CD4 T cell immunity
in the absence of IL-15. Direct association of CD4 T cell defect
with increased survival or decreased pathology in IL-15/ mice is
conclusively demonstrated by adoptive transfer of immuneCD4T
cells to these animals. T. gondii infection in these knockout recip-
ients results in gut pathology similar to the WT animals.
Based on previous observations and our current findings, the
hypothesis we propose is as follows: T. gondii infection induces a
strong activation of DCs, which are important for antigen presen-
tation (29) and induction of CD4 T cell immune response (29).
IL-15 seems to be a critical factor for activation of DCs, and in the
absence of this gene, DCs are unable to induce adequate antigen-
specific CD4 T cell levels in the host. Although this subdued DC
response inhibits the clearance of the parasite, the inflammatory
process at these sites is subdued, thus preventing mortality. Our
studies raise some important issues. (i) Is the lower CD8 T cell
response reported in the absence of functional IL-15 (33) due to
down-regulated CD4 T cell immune response in these animals?
(ii) Is the suboptimal CD4 T cell priming by DCs in IL-15/mice
due to the lower NK cell response described in these animals (33)?
NK cells, by their ability to produce IFN-, have been recently
shown to play an important role in the activation of DCs (53). To
our knowledge, this is the first report that demonstrates that IL-15
has a role in priming of CD4 T cell response. These studies have
strong implications for inflammatory or autoimmune diseases
where targeting of IL-15 may dampen the severity because of
down-regulation of CD4 T cell response.
Materials and Methods
Mice and Parasites. Six- to 8-week-old female IL-15/ (Taconic),
IFN-/ (The Jackson Laboratory), and C57BL6 (WT) (The
Jackson Laboratory) mice were maintained in a specific pathogen-
free environment in the animal research facility at the Louisiana
State University Health Sciences Center. All experiments were
performed in accordance with Institutional Animal Care and Use
Committee regulations. Mice were challenged p.o. with 20–25 cysts
of T. gondii strain 76K, which was maintained by continuous oral
passage of cysts through C57BL6 mice (Charles River Breeding
Laboratories). TLA was prepared as described in ref. 10.
Histopathology. Infected mice from both knockout andWT groups
were killed on days 8–10 p.i., and tissues (liver and gut) were
collected. The tissues were fixed in buffered 10% formalin, em-
bedded, sectioned, and stained with hematoxylineosin for histo-
logical examination. Sections were examined and photographed on
Kodak T-MAX film with an Olympus Van Ox photomicroscope.
Quantification of Parasite Load. IL-15/ and WT mice were in-
fected orally as described above. Quantification of parasite burden
on the tissues (spleen, liver, gut, and brain) was performed at day
10 p.i. by quantitative PCR as described in ref. 54.
ActivationMarkers. IL-15/ andWTmicewere orally infectedwith
20–25 cysts of T. gondii as described above. At day 10 p.i., the mice
were killed, MLNs were removed, and cell suspensions were
prepared. Cells were labeled with anti-CD4 FITC conjugated,
anti-CD44 CyChrome conjugated, and anti-CD62L PE conjugated
(eBioscience, San Jose, CA) in PBS-BSA 0.5% for 1 h. Cells were
washed several times in buffer, fixed in 1% formaldehyde, and
stored at 4°C until acquisition on a FACSVantage system (BD
Biosciences).
Cytokine Assay. IFN- production by T cells was evaluated by
intracellular staining at day 10 p.i. as described in ref. 18, using the
CytofixCytoperm kit (BD Pharmingen).
In Vitro IL-12 Production by DCs. DCs were isolated from MLN of
naı¨ve mice by positive selection by means of magnetic sorting
(Miltenyi Biotech) using anti-CDllc beads and according to the
manufacturer’s instructions. Cells were further purified by flow
cytometry, and 96% pure CD11chi cells were plated in 96-well
plates at concentrations of 5  104 cells per well. Cultures were
treated with TLA (20 gml) and recombinant mouse IL-15 (50
ngml) (R&D Systems). After overnight incubation, supernatants
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were collected and assayed for IL-12 production by using cytokine
ELISA kit (BioLegend, San Diego) according to the manufactur-
er’s instructions.
Detection of IFN- Message. IFN- message in the guts of infected
animals was determined by real-time PCR. At day 7 p.i., mice were
killed and total tissue RNA was extracted by using TRIzol reagent
(Life Technologies). DNA was removed from the extracted RNA
according to the standard protocol (55), and RNA was further
purified by using the RNeasy spin column (Qiagen). For RT-PCR,
2 g of RNA was reverse-transcribed by using the SuperScript III
first-strand synthesis system (Invitrogen Life Technologies). Am-
plification was performed by real-time fluorogenic PCR with the
SmartMix HM bead (Cepheid, Sunnyvale, CA) on a Cepheid
SmartCycler. Each reaction contained one lyophilized SmartMix
HM bead, SYBR green I (Cambrex Bio Science Rockland, Rock-
land, ME), and either 200 nM murine IFN- forward and reverse
primers (56) or 400 nM -actin forward and reverse primers (57)
(Integrated DNA Technologies, Coralville, IA). Samples were
subjected to 40 cycles of 15 s at 95°C and 1 min at 60°C followed by
melt curve analysis as described in ref. 56.
Adoptive Transfer of CD4 T Cells. CD4 T cells fromWTC57BL6
or IFN-/ mice infected p.o. with 20 cysts 10 days earlier were
transferred to IL-15/ mice by the i.v. route. Briefly, mesenteric
lymphocytes fromC57BL6mice were collected, and CD4 T cells
were isolated by positive selection via MACS purification, using
anti-CD4 biotinylated antibody and anti-biotin beads (Miltenyi
Biotech). Purified CD4 T cells (1  107; 95% pure) were
administered i.v. to IL-15/mice. Recipients were challenged p.o.
with 25 cysts of T. gondii 1 day posttransfer. The animals were
monitored for survival on a daily basis.
CD4 T Cell Proliferation.CD4T cells fromC57BL6 and IL-15/
mice were isolated fromMLN as described above. Antigen-specific
proliferation of purified CD4 T cells was determined by [3H]thy-
midine incorporation as described in ref. 9.
In a separate series of experiments, in vitro priming of CD4 T
cells byDCswas performed. PurifiedDCs fromMLNof naı¨vemice
were cultured as mentioned above. The next day, 1  105 purified
CD4 T cells from pooled MLN were added, cultures were
incubated for 4 days, and proliferation of CD4 T cells was
determined.
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